These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
147 related articles for article (PubMed ID: 25488087)
61. Longitudinal screening algorithm that incorporates change over time in CA125 levels identifies ovarian cancer earlier than a single-threshold rule. Drescher CW; Shah C; Thorpe J; O'Briant K; Anderson GL; Berg CD; Urban N; McIntosh MW J Clin Oncol; 2013 Jan; 31(3):387-92. PubMed ID: 23248253 [TBL] [Abstract][Full Text] [Related]
62. The value of 18F-FDG PET/CT imaging combined with detection of CA125 and HE4 in the diagnosis of recurrence and metastasis of ovarian cancer. Sun J; Cui XW; Li YS; Wang SY; Yin Q; Wang XN; Gu L Eur Rev Med Pharmacol Sci; 2020 Jul; 24(13):7276-7283. PubMed ID: 32706065 [TBL] [Abstract][Full Text] [Related]
64. Alternatives to risk-reducing surgery for ovarian cancer. Gadducci A; Sergiampietri C; Tana R Ann Oncol; 2013 Nov; 24 Suppl 8():viii47-viii53. PubMed ID: 24131970 [TBL] [Abstract][Full Text] [Related]
65. Early detection of ovarian cancer in samples pre-diagnosis using CA125 and MALDI-MS peaks. Timms JF; Menon U; Devetyarov D; Tiss A; Camuzeaux S; McCurrie K; Nouretdinov I; Burford B; Smith C; Gentry-Maharaj A; Hallett R; Ford J; Luo Z; Vovk V; Gammerman A; Cramer R; Jacobs I Cancer Genomics Proteomics; 2011; 8(6):289-305. PubMed ID: 22086897 [TBL] [Abstract][Full Text] [Related]
66. Ultrasound screening of ovarian cancer. Bäumler M; Gallant D; Druckmann R; Kuhn W Horm Mol Biol Clin Investig; 2019 Sep; 41(3):. PubMed ID: 31661436 [TBL] [Abstract][Full Text] [Related]
67. Ovarian cancer screening in the high-risk population--the UK Familial Ovarian Cancer Screening Study (UKFOCSS). Rosenthal AN Int J Gynecol Cancer; 2012 May; 22 Suppl 1():S27-8. PubMed ID: 22543917 [No Abstract] [Full Text] [Related]
68. CA125 and transvaginal ultrasound monitoring in high-risk women cannot prevent the diagnosis of advanced ovarian cancer. Olivier RI; Lubsen-Brandsma MA; Verhoef S; van Beurden M Gynecol Oncol; 2006 Jan; 100(1):20-6. PubMed ID: 16188302 [TBL] [Abstract][Full Text] [Related]
69. Ovarian cancer screening and mortality. Menon U; Gentry-Maharaj A; Jacobs I JAMA; 2011 Oct; 306(14):1544; author reply 1544-5. PubMed ID: 21990294 [No Abstract] [Full Text] [Related]
70. New tumor markers: CA125 and beyond. Bast RC; Badgwell D; Lu Z; Marquez R; Rosen D; Liu J; Baggerly KA; Atkinson EN; Skates S; Zhang Z; Lokshin A; Menon U; Jacobs I; Lu K Int J Gynecol Cancer; 2005; 15 Suppl 3():274-81. PubMed ID: 16343244 [TBL] [Abstract][Full Text] [Related]
71. Limitations to the use of the CA-125 antigen level in ovarian cancer. Markman M Curr Oncol Rep; 2003 Jul; 5(4):263-4. PubMed ID: 12781066 [No Abstract] [Full Text] [Related]
72. Preoperative detection of ovarian cancer by color Doppler ultrasonography and CA 125. Hossain F; Karim MN; Rahman SM; Khan N; Siddiqui M; Hussain R Bangladesh Med Res Counc Bull; 2010 Aug; 36(2):68-73. PubMed ID: 21473205 [TBL] [Abstract][Full Text] [Related]
73. Use of CA125 and HE4 serum markers to predict ovarian cancer in elevated-risk women. Karlan BY; Thorpe J; Watabayashi K; Drescher CW; Palomares M; Daly MB; Paley P; Hillard P; Andersen MR; Anderson G; Drapkin R; Urban N Cancer Epidemiol Biomarkers Prev; 2014 Jul; 23(7):1383-93. PubMed ID: 24789859 [TBL] [Abstract][Full Text] [Related]
74. CA125 in ovarian cancer: European Group on Tumor Markers guidelines for clinical use. Duffy MJ; Bonfrer JM; Kulpa J; Rustin GJ; Soletormos G; Torre GC; Tuxen MK; Zwirner M Int J Gynecol Cancer; 2005; 15(5):679-91. PubMed ID: 16174214 [TBL] [Abstract][Full Text] [Related]
75. Screening for ovarian cancer. Quinn MA Aust Fam Physician; 2001 Jun; 30(6):530-4. PubMed ID: 11458578 [TBL] [Abstract][Full Text] [Related]
76. The Diagnostic Value of Transvaginal Sonograph (TVS), Color Doppler, and Serum Tumor Marker CA125, CEA, and AFP in Ovarian Cancer. Zhang F; Zhang ZL Cell Biochem Biophys; 2015 Jun; 72(2):353-7. PubMed ID: 25582421 [TBL] [Abstract][Full Text] [Related]
77. Differentiation between ovarian metastasis from colorectal carcinoma and primary ovarian carcinoma: Evaluation of tumour markers and "mille-feuille sign" on computed tomography/magnetic resonance imaging. Kurokawa R; Nakai Y; Gonoi W; Mori H; Tsuruga T; Makise N; Ushiku T; Abe O Eur J Radiol; 2020 Mar; 124():108823. PubMed ID: 31935596 [TBL] [Abstract][Full Text] [Related]
78. Preoperative sensitivity and specificity for early-stage ovarian cancer when combining cancer antigen CA-125II, CA 15-3, CA 72-4, and macrophage colony-stimulating factor using mixtures of multivariate normal distributions. Skates SJ; Horick N; Yu Y; Xu FJ; Berchuck A; Havrilesky LJ; de Bruijn HW; van der Zee AG; Woolas RP; Jacobs IJ; Zhang Z; Bast RC J Clin Oncol; 2004 Oct; 22(20):4059-66. PubMed ID: 15381683 [TBL] [Abstract][Full Text] [Related]
79. The application value of the detection of the level of tissue polypeptide antigen, ovarian cancer antigen X1, cathepsin L and CA125 on the diagnosis of epithelial ovarian cancer. Lv XL; Zhu Y; Liu JW; Ai H Eur Rev Med Pharmacol Sci; 2016 Dec; 20(24):5113-5116. PubMed ID: 28051260 [TBL] [Abstract][Full Text] [Related]
80. Ovarian cancer screening: Current status and future directions. Nash Z; Menon U Best Pract Res Clin Obstet Gynaecol; 2020 May; 65():32-45. PubMed ID: 32273169 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]